

Steven Edland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2947276/publications.pdf>

Version: 2024-02-01

37
papers

1,501
citations

430874

18
h-index

434195

31
g-index

43
all docs

43
docs citations

43
times ranked

2844
citing authors

#	ARTICLE	IF	CITATIONS
1	Power formulas for mixed effects models with random slope and intercept comparing rate of change across groups. <i>International Journal of Biostatistics</i> , 2022, 18, 173-182.	0.7	4
2	Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease. <i>Neurology</i> , 2022, 98, .	1.1	9
3	Sex and <i>APOE</i> ϵ 4 modify the effect of cardiovascular risk on tau in cognitively normal older adults. <i>Brain Communications</i> , 2022, 4, fcac035.	3.3	8
4	Age-at-Onset and <i>APOE</i> -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2272-e2283.	1.1	15
5	Shortening heparan sulfate chains prolongs survival and reduces parenchymal plaques in prion disease caused by mobile, ADAM10-cleaved prions. <i>Acta Neuropathologica</i> , 2020, 139, 527-546.	7.7	23
6	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. <i>Neurology</i> , 2020, 94, e2076-e2087.	1.1	42
7	Counterpoint to Jin et al, On weighted composite scores for early Alzheimer's trials. <i>Pharm Stat.</i> 18 (2):239-47, 2019, DOI: 10.1002/pst.1920. <i>Pharmaceutical Statistics</i> , 2020, 19, 492-493.	1.3	0
8	MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 1322-1332.	0.8	37
9	Concepts for brain aging: resistance, resilience, reserve, and compensation. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 22.	6.2	81
10	Sex-specific composite scales for longitudinal studies of incipient Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 508-514.	3.7	9
11	Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 75, 169-177.	3.1	13
12	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.8	310
13	Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 561-569.	0.8	25
14	P331: LIFETIME ALCOHOL INTAKE IS ASSOCIATED WITH AGING-RELATED COGNITIVE DECLINE: THE HONOLULU-ASIA AGING STUDY (HAAS). <i>Alzheimer's and Dementia</i> , 2018, 14, P1207.	0.8	0
15	TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1549-1558.	2.6	16
16	Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. <i>MBio</i> , 2018, 9, .	4.1	48
17	Effects of Military Service on Marital Stability Among World War II U.S. Veterans of Japanese Descent. <i>Military Medicine</i> , 2018, 183, e525-e531.	0.8	3
18	Design of pilot studies to inform the construction of composite outcome measures. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 213-218.	3.7	8

#	ARTICLE	IF	CITATIONS
19	NPTX2 and cognitive dysfunction in Alzheimer's Disease. <i>ELife</i> , 2017, 6, .	6.0	146
20	P3-007: Optimal Composite Volumetric MRI Endpoints in Longitudinal Studies of Neurodegenerative Disease: Proof-of-Concept Demonstration in Primary Progressive Aphasia. <i>Alzheimer's and Dementia</i> , 2016, 12, P820.	0.8	0
21	Smoking prevalence in urban and rural populations: findings from California between 2001 and 2012. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 152-161.	2.1	10
22	Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 31, 72-78.	2.2	49
23	Proof of concept demonstration of optimal composite MRI endpoints for clinical trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 177-181.	3.7	9
24	Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. <i>Neurology</i> , 2016, 86, 1000-1008.	1.1	141
25	The differential associations of preexisting conditions with trauma-related outcomes in the presence of competing risks. <i>Injury</i> , 2016, 47, 677-684.	1.7	7
26	P1-209: Cerebral amyloid angiopathy is not associated with late-life cognitive performance in the Honolulu Asia aging study. , 2015, 11, P430-P431.		0
27	Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. <i>Pharmaceutical Statistics</i> , 2015, 14, 418-426.	1.3	24
28	Elucidating Molecular Phenotypes Caused by the SORL1 Alzheimer's Disease Genetic Risk Factor Using Human Induced Pluripotent Stem Cells. <i>Cell Stem Cell</i> , 2015, 16, 373-385.	11.1	143
29	Pulse Pressure in Relation to Tau-Mediated Neurodegeneration, Cerebral Amyloidosis, and Progression to Dementia in Very Old Adults. <i>JAMA Neurology</i> , 2015, 72, 546.	9.0	101
30	Smokers who report smoking but do not consider themselves smokers: a phenomenon in need of further attention: Table 1. <i>Tobacco Control</i> , 2015, 24, 400-403.	3.2	19
31	F3-02-03: OPTIMALLY WEIGHTED ENDPOINTS FOR CLINICAL TRIALS IN MILD COGNITIVE IMPAIRMENT AND PRE-CLINICAL ALZHEIMER'S DISEASE. , 2014, 10, P204-P204.		0
32	F4-02-01: Evidence of learning or placebo effects relevant to clinical trials of mild cognitive impairment. , 2013, 9, P676-P676.		0
33	Power Calculations for Clinical Trials in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 369-377.	2.6	59
34	NIA-Funded Alzheimer Centers Are More Efficient than Commercial Clinical Recruitment Sites for Conducting Secondary Prevention Trials of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 159-164.	1.3	20
35	Neuroimaging Enrichment Strategy for Secondary Prevention Trials in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 269-277.	1.3	42
36	The net effect of alternative allocation ratios on recruitment time and trial cost. <i>Clinical Trials</i> , 2009, 6, 126-132.	1.6	19

#	ARTICLE	IF	CITATIONS
37	ADCS Prevention Instrument Project: Overview and Initial Results. Alzheimer Disease and Associated Disorders, 2006, 20, S109-S123.	1.3	60